Adicet Bio Inc

NASDAQ:ACETUnited States

Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Contact Information

Headquarters

131 Dartmouth Street, 3Rd FloorBOSTON, MA, United States 02116

Phone

617-482-2333

Fax

302-655-5049

Executives

Independent Chairman of the Board

Carl Gordon

President, Chief Executive Officer, Director

Chen Schor

Chief Financial Officer

Nick Harvey

Chief Technology Officer

Donald Healey

Chief Scientific Officer

Blake Aftab